Pacer Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Pacer Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-184	Closed	-$66K	–	1420
2021 Q1	$66K	Buy	184 +62	+51%	+$27.4K	﹤0.01%	1395
2020 Q4	$60K	Sell	122 -37	-23%	-$17.1K	﹤0.01%	1401
2020 Q3	$52K	Buy	+159	New	+$54.1K	﹤0.01%	1304
2018 Q4	–	Sell	-208	Closed	-$215K	–	570
2018 Q3	$215K	Buy	+208	New	+$203K	0.01%	1022

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pacer Advisors's ATRA Position: Q2 2021 in Review

Pacer Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 184 shares — an estimated $66K sold.

Pacer Advisors first reported a position in ATRA in Q3 2018 and held it in 4 quarters. The position peaked at $215K in Q3 2018. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

Pacer Advisors reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 184 Atara Biotherapeutics shares in Q2 2021, an estimated $66K.
Pacer Advisors first reported a position in Atara Biotherapeutics in Q3 2018 and held it in 4 quarters.
Pacer Advisors's Atara Biotherapeutics position peaked at $215K in Q3 2018.
145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.